CHEMOTHERAPY +/- ADDITIONAL CHEMOTHERAPY AND/OR XRT IN HODGKIN'S DISEASE

化疗 /- 霍奇金病的额外化疗和/或 XRT

• 批准号: 7607510
• 负责人: YOUSIF H MATLOUB
• 金额: $ 0.3万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607510
• 关键词: Blood; Chemotherapy-Oncologic Procedure; Child; Clinical Trials; Combination Chemotherapy; Computer Retrieval of Information on Scientific Projects Database; Count; Databases; Drug usage; Filgrastim; Funding; Grant; Hodgkin Disease; Infusion procedures; Injection of therapeutic agent; Institution; National Cancer Institute; Newly Diagnosed; Oral cavity; Patients; Pharmaceutical Preparations; Phase III Clinical Trials; Physician Data Query; Prednisone; Radiation therapy; Randomized; Research; Research Personnel; Resources; Source; Time; United States National Institutes of Health; Week; Work; cancer cell; chemotherapy; day; killings; Blood; Chemotherapy-Oncologic Procedure; Child; Clinical Trials; Combination Chemotherapy; Computer Retrieval of Information on Scientific Projects Database; Count; Databases; Drug usage; Filgrastim; Funding; Grant; Hodgkin Disease; Infusion procedures; Injection of therapeutic agent; Institution; National Cancer Institute; Newly Diagnosed; Oral cavity; Patients; Pharmaceutical Preparations; Phase III Clinical Trials; Physician Data Query; Prednisone; Radiation therapy; Randomized; Research; Research Personnel; Resources; Source; Time; United States National Institutes of Health; Week; Work; cancer cell; chemotherapy; day; killings

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease. This randomized Phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Patients will receive infusions or injections of combination chemotherapy on Days 1-3 and 8. They will also receive prednisone by mouth two or three times a day on Days 1-7. Beginning on Day 4, patients will also receive injections of filgrastim once a day (except Day 8) until blood counts return to normal. Treatment may be repeated every 3 weeks for up to two courses. Patients will then be assigned to one of two groups. Patients in Group 1 will receive two additional courses of the initial chemotherapy regimen, followed by either radiation therapy or no further treatment. Patients in Group 2 will be randomly assigned to one of two groups to receive either two courses of another chemotherapy regimen plus two additional courses of the initial chemotherapy regimen, followed by radiation therapy OR two additional courses of the initial chemotherapy regimen followed by radiation therapy. Patients will be evaluated every 3 months for 2 years, every 6 months for 3 years, and once a year thereafter.

该副本是使用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这是调查员的机构。 （来自国家癌症研究所数据库的临床试验摘要） 化学疗法中使用的药物使用不同的方法来阻止癌细胞分裂，从而停止生长或死亡。以不同组合的形式提供药物可能会杀死更多的癌细胞。放射疗法使用高能X射线来损害癌细胞。尚不清楚化学疗法是否在治疗霍奇金氏病中更有效，或者没有其他化学疗法和/或放射疗法。 这项随机III期试验正在研究接受或不进行放射治疗的不同化学疗法方案，以比较他们在治疗新诊断的霍奇金氏病儿童方面的工作状况。 患者将在第1-3天和第8天接受输注或组合化学疗法的注射。他们还将在1-7天每天接受两次或三次的口腔泼尼松。从第4天开始，患者还将每天一次注射一次Filgrastim（第8天除外），直到血液计数恢复正常为止。 可以每3周重复一次治疗，最多两课。然后将患者分配给两组之一。第1组的患者将接受另外两种初始化疗方案，然后再进行放射治疗或没有进一步的治疗。第2组的患者将随机分配给两组之一，以接受另一种化学疗法方案的两种课程，以及初始化学疗法方案的另外两个课程，然后进行放射治疗或两种初始化疗方案的另外两种课程，然后进行放射治疗。 将每3个月每3个月，每6个月进行3年和每年一次评估患者。